🚨Another big win for #precisionmedicine 🚨👉🏼Today the FDA approved lirafugratinib for FGFR2‑rearranged cholangiocarcinoma. ⭐️I still remember the first patient in the universe we enrolled on the trial during the peak of the pandemic. Three days in - I called the amazing Ben- the then CMO of @Relay_Tx “Your drug is working, working too good. We need to work on the right dosing & get it right for patients. I think this baby will graduate someday.” That day is today 🙌🏼 Thankful to all patients who volunteered & the amazing teams that got this to finish line 🙏🏽 !!! @OncoAlert @oncodaily @OncBrothers @ElizSMcKenna @matthewherper @curecc @Aiims1742 @MiteshBorad @AliSchram 👉🏼Link to FDA approval fda.gov/drugs/resources-info… 👉🏼Link to @CD_AACR @AACR bench to bedside publication aacrjournals.org/cancerdisco…

Join me!

Congratulations @EileenMOReilly @MSKCancerCenter @MSK_DeptOfMed Brian Wolpin Ziv Wainberg and all colleagues on a long awaited and badly needed game changer in #pancreascancer

Beyond grateful to @ConquerCancerFd @ASCO for the incredible support over the years which has fueled my career and facilitated drug development in rare cancers, improving the lives of patients. conquer.org/patient-impact/a…

Relay announces data for Zovegalisib (PI3Ki) plus Atirmociclib (CDK4i) Triplet Combination in late line MBC: 44% ORR in heavily pre-treated, CDK4/6-experienced patients (median third-line). Plan to start a first-line phase 3 trial in 2026. globenewswire.com/news-relea…

Next-generation sequencing (NGS) is revolutionizing the ovarian cancer landscape. In this interview, @AliSchram (@MSKCancerCenter) highlights the critical role of early NGS testing and the shift toward personalized, biomarker-driven therapies. #SGOAM26 targetedonc.com/view/emergin…

When a phase 1 trial is published in @NEJM, you can bet it will be impactful. Here, the p53 reactivator rezatapopt showed an ORR 20% among 77 pts with TP53 mutant (Y220C) advanced tumors. Are we getting closer to drug the most undruggable of all mutations? nejm.org/doi/full/10.1056/NE…

Now available on pubmed! Results of the zenocutuzumab (Bizengri) basket trial in NRG1 fusion + solid tumors. This trial led to recent FDA approval in lung and pancreatic cancer. RNA seq is critical to identify these fusions. 🧬@NEJM pubmed.ncbi.nlm.nih.gov/3990…

#ICYMI, the FDA recently approved zenocutuzumab for NSCLC with an NRG1 fusion! Catch this all-new episode of #LungCancerConsidered as @StephenVLiu and @AliSchram discuss this breakthrough and what this approval means for treating NSCLC patients with an NRG1 fusion. 🔗 Listen now: bit.ly/FDAZenocutuzumab #LungCancer #NSCLC #Oncology #FDAApproval

I am commonly asked what the benchmarks are for a target-drug pair to have tumor-agnostic potential. See the new ETAC-S! @Annals_Oncology @myESMO @VivekSubbiah @JulianaRBeal @curijoey @Dr_R_Kurzrock @SewantiLimaye @StefanMichiels @quimmateo @niamhjcoleman @FAndreMD @ElenaGarralda

I second this. Pat you are a powerhouse, role model, mentor, brilliant trialist and compassionate doctor. AACR is in the best hands. Congrats! @AACRPres

Fun session thanks to @VivekSubbiah, Christophe Le Tourneau, and Jordi Rodon complete with a sonnet about tumor agnostic drug development by ChatGPT/Vivek! 🎯🧬💊😂

⭐️Mark your calendars if you are attending the triple meeting 👉 Super thrilled to be discussing about the "Future of Tissue-Agnostic Drug Development" with an amazing panel of speakers at the AACR-NCI-EORTC @AACR @theNCI @EORTC #Targets23 Boston #PrecisionMedicine @AliSchram @OncoAlert 🎯🧬

Don't miss @AliSchram explaining class II and III BRAF alterations. hmpgloballearningnetwork.com…

Well deserved! @TinaJost4 I hope you continue this great work on the mechanism of radiosensitization and most effective use of DDR therapies

We are pleased to announce our manuscript on pan-cancer multi-PIK3CA mutations, published this week in @CCR_AACR. nitter.siddz.com/smruthy90/status/16106…

🎯On behalf of all co-investigators presenting👉Identifying FGFR2 fusions/rearrangements in cholangiocarcinoma using a novel cfDNA algorithm for treatment w RLY-4008, a highly selective irreversible FGFR2 inhibitor #ENAsymp22 @AliSchram @OncoAlert @Relay_Tx

In case you missed it, updated results from the eNRGy study presented at #ASCO22! Zeno ORR of 34% (27/79) across tumor types & 42% (8/19) in PDAC. Median DOR of 9.1 mo and extremely well tolerated. Zeno has the potential to become new SOC for this unmet clinical need.

Grateful to be involved in this exciting study demonstrating efficacy targeting the elusive p53 (Y220C). Cool biology and helping patients!

Despite having lost her voice, @HillaSolomon told us all about her group's research on possible #EndometrialCancer treatment options that led to a #ClinicalTrial at MSK. @Rev_Medicine @RadhaMukherjee1 @AliSchram #AACR22